ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

Mylan Confirms Endo Suit Over Generic Migraine Drug Application

DOW JONES NEWSWIRES Mylan Inc. (MYL) confirmed Wednesday that it has been sued by Endo Pharmaceuticals Holdings Inc. (ENDP) over its application for approval of a generic drug used to treat acute migraine headaches in adults. Mylan--one of the world's largest generic drug makers--said it believes it is the first company to file a substantially complete application for approval of frovatriptan succinate EQ, a generic version of Frova. The company said it expects to qualify for 180 days of marketing exclusivity upon final approval from the Food and Drug Administration. Mylan, which has had litigation-related charges figure prominently in its recent quarterly results, last month reported second-quarter earnings surged 70% as sales got a lift from a weaker dollar. Shares closed Tuesday at $20.01 and were inactive in recent premarket trade. Through the latest close, the stock is down 5.3% since the start of the year. -By Mia Lamar, Dow Jones Newswires; 212-416-3207;

Stock News for Mylan Inc. (MYL)
11/28/201507:00:033 Healthcare Stocks With Massive Buyback Programs
11/24/201507:30:00Mylan Launches Generic FazaClo® Orally Disintegrating Tablets
11/24/201505:34:00Mylan EPD au Canada lance MyFreshStart™ pour les patients qui p...
11/23/201508:00:00Mylan EPD in Canada Launches MyFreshStart™ for Patients Taking M...
11/20/201517:04:36Proxy Statement - Notice of Shareholders Meeting (preliminary...
11/20/201507:30:00Mylan Completes Acquisition of Certain Businesses from Famy Care...
11/19/201515:26:00Mylan Confirms First-to-File Patent Challenge Relating to DELZICOL®
11/19/201513:50:00Mylan Launches Generic Adderall® Tablets
11/19/201503:02:00Shares Of Deal Targets Reflect Regulatory Fear
11/17/201507:30:00Mylan Launches Generic AXERT® Tablets
11/16/201512:50:00Mylan to Buy Back $1 Billion in Stock
11/16/201511:40:00Mylan Authorizes $1 Billion Share Repurchase Plan
11/16/201507:30:00Mylan Launches Generic Viramune XR® Extended-Release Tablets...
11/16/201507:00:00Mylan Launches Generic GLUCOTROL XL® Tablets
11/15/201507:20:02Generic Drugmakers Block Suitors, but Is That Good or Bad News?
11/13/201512:34:03Mylan N.V.'s Hostile Takeover Attempt of Perrigo Fails -- Investors...
11/13/201510:08:00Mylan Loses Hostile Bid for Perrigo--2nd Update
11/13/201509:40:00Mylan Loses Hostile Bid for Perrigo
11/13/201509:34:00Mylan Loses Hostile Bid for Perrigo--Update
11/13/201508:39:00Mylan Announces Results of Offer to Acquire Perrigo and Lapse...

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations